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Abstract
Background The United Kingdom (UK) bowel cancer screening programme has reduced mortality from colorectal cancer 
(CRC), but poor uptake with stool-based tests and lack of specificity of faecal occult blood testing (FOBT), has prompted 
investigation for a more suitable screening test. The aim of this study was to investigate the feasibility of a urinary volatile 
organic compounds (VOC)-based screening tool for CRC.
Methods The urine from FOBT-positive patients was analysed using field asymmetric ion mobility spectrometry (FAIMS) 
and gas chromatography coupled with ion mobility spectrometry (GC–IMS). Data were analysed using a machine learn-
ing algorithm to calculate the test accuracy for correct classification of CRC against adenomas and other gastrointestinal 
pathology.
Results One hundred and sixty-three patients were enrolled in the study. Test accuracy was high for differentiating CRC 
from control: area under the curve (AUC) 0.98 (95% CI 0.93–1) and 0.82 (95% CI 0.67–0.97) using FAIMS and GC–IMS 
respectively. Correct classification of CRC from adenoma was high with AUC range 0.83–0.92 (95% CI 0.43–1.0). Classifi-
cation of adenoma from control was poor with AUC range 0.54–0.61 (95% CI 0.47–0.75) using both analytical modalities.
Conclusions CRC was correctly distinguished from adenomas or no bowel pathology using urinary VOC markers, within 
the bowel screening population. This pilot study demonstrates the potential of this method for CRC detection, with higher 
test uptake and superior sensitivity than FOBT. In addition, this is the first application of GC–IMS in CRC detection which 
has shown high test accuracy and usability.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer-related 
deaths in the western world [1, 2]. It represents the fourth 
most common cancer in England and Wales and is the sec-
ond leading cause of cancer-related deaths [1].
The United Kingdom (UK) bowel cancer screen-
ing programme (UK BCSP) was implemented in 2007 
following a series of randomised controlled trials that 
demonstrated a reduction in mortality from CRC due to 
screening [3–6]. However, the current guaiac FOBT has 
a number of well-documented disadvantages including 
low uptake (around 60%), low specificity and the test 
interpretation has the potential for human error [7, 8]. The 
introduction of the faecal immunochemical test (FIT) as 
the first-line bowel screening test in the UK is anticipated 
within the next year and is associated with improved 
uptake by as much as 25% and higher sensitivity [7, 9]. 
However, overall test accuracy could be improved fur-
ther, to detect more CRC cases via screening and prevent 
unnecessary colonoscopies.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1015 1-019-01963 -6) contains 
supplementary material, which is available to authorized users.
 * E. Mozdiak 
 ella.mozdiak@nhs.net
1 University Hospitals Coventry and Warwickshire, Coventry, 
UK
2 School of Engineering, The University of Warwick, 
Coventry, UK
344 Techniques in Coloproctology (2019) 23:343–351
1 3
There is a dearth of research on new biomarkers for 
CRC detection. One area that has gained momentum over 
the past decade is the use of volatile organic compounds 
(VOCs). VOCs are organic chemicals that have a high 
vapour pressure at room temperature, i.e. that evaporate 
or sublimate readily under ambient conditions. They can 
be captured from a variety of body mediums and have been 
shown to alter in different disease states [10, 11].
Applying the use of gas phase markers to diagnose CRC 
is a rapidly expanding area, but it involves highly com-
plex sample and data analysis. Detection of VOCs in CRC 
using a variety of different mediums has been investigated 
in small-scale studies [12–14]. Few have used urine analy-
sis or focussed on the asymptomatic BCSP cohort. There 
are currently no VOC-based tests established in the clini-
cal setting for any disease [15–18].
Using urine for VOC detection has the advantage that 
urine is simple to collect and is readily available and col-
lection is associated with high patient acceptability. It is 
also easy to store and shows stability in the medium term 
[19]. These factors make it an ideal focus for the develop-
ment of a screening tool as an alternative to a faeces-based 
test.
This study aims to establish whether urinary VOC 
markers can be utilised as a tool for detecting CRC and 
adenomas within the UK BCSP. Sample analysis was con-
ducted using field asymmetrical ion mobility spectrometry 
(FAIMS), which has been employed in a small number 
of studies before [20–23]. In addition, a new analytical 
modality for disease detection called gas chromatography 
coupled with ion mobility spectrometry (GC–IMS) was 
employed.
Materials and methods
All enrolled patients were recruited from the Coventry 
and Warwickshire University Hospitals between April 
2015 and November 2016. Regional ethical approval was 
granted by the Warwickshire Research and Development 
Department and Warwickshire Ethics Committee 09/
H1211/38. Informed consent was obtained from the indi-
vidual participants that took part in the study. This study 
was approved by the bowel cancer screening research com-
mittee only to approach those that had a positive FOBT 
test.
Patient recruitment
Patients were recruited from the nurse-led BCSP clinics fol-
lowing a positive FOBT result. Consent and urine sample 
collection were carried out at the clinic prior to bowel prepa-
ration administration. A total of 181 patients were invited 
to participate and 163 consented to provide samples for the 
final analysis.
Sample collection and storage
Two 20 ml samples of urine were collected. Samples were 
immediately transferred to − 20  °C storage and then to 
− 80 °C within 24 h for long-term storage. Diagnostic out-
come data were collected from the colonoscopy or computed 
tomography (CT) colonography result, histology was con-
firmed from the pathology report.
Sample analysis
Samples were analysed using the Lonestar FAIMS instru-
ment (Owlstone, UK) and the Silox GC–IMS (Imspex, UK). 
FAIMS is a gas detection technology that separates chemi-
cal ions, within a complex mixture of VOCs, based on their 
mobility/movement in high electrical fields. This technique 
has been described in detail before. Sampling methods can 
be found in previous publications by our group [12, 23]. A 
detailed schematic for FAIMS analysis is found in Online 
Resource 1.
GC–IMS involves a two-stage analytical process. The 
first stage uses a gas chromatograph to separate VOCs based 
on their interaction with a coated capillary column. Then 
these VOCs are detected as they elude from the column 
using a drift-tube ion mobility spectrometer, where the time 
taken for chemical ions to travel along a tube (against a flow 
of buffer gas) is measured. Chemical ions of different sizes 
take different lengths of time to travel along the tube and 
this can be used to separate chemical species. As this has 
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Fig. 1  Schematic of the separa-
tion process and ion detection 
using gas chromatography–
ion mobility spectrometry 
(GC–IMS). (1) Sample passes 
through the gas column where 
initial separation occurs. (2) 
The discrete compounds are 
consecutively fed into the ioni-
sation chamber where ionisation 
occurs. (3) Ions pass through 
the drift tube at varying speeds 
dependent on their mobility. 
(4) Ions hit the sensor plate and 
are detected. (5) Ion peaks are 
calculated based on drift time
Fig. 2  Three-dimensional representation of gas chromatography (GC) 
data output with corresponding ion mobility spectrometry (IMS) 
chromatogram. (1). Single IMS spectra data is combined with GC run 
time peaks. (2) Heatmap corresponding to GC–IMS peaks (yellow 
and blue lines) (Image adapted with permission from Impsex, UK). 
Data output is twofold: gas chromatography (GC) gives peaks rep-
resenting retention time as the ions pass thorough the column. This 
is coupled with ion mobility spectrometry (IMS) data, based on the 
mobility of the ions as they pass through the drift tube and hit the 
sensor. The culmination of this two-phase analysis is represented as 
an IMS chromatogram which incorporates millions of data points in a 
heatmap (Fig. 2). These data points are subject to very similar statisti-
cal analysis as is applied to the Lonestar data
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not previously been described sample analysis is outlined 
here:
A 5 ml urine sample is aliquoted into a 20 ml glass vial 
and sealed with a crimp lid. A 21 g needle is attached to 
the GC–IMS input port. The needle with attached port is 
inserted into the sample headspace 1 cm above the urine. 
The needle is held in place for 20 s to allow for vapour 
aspiration. The total run time is 5 min per sample. The 
carrier gas flow rate is 150 ml/min and sample flow rate 
through the instrument is 20 ml/min. The sample heating 
was carried out in accordance with manufacturer instruc-
tions to a maximal level of 80 °C. A schematic for the 
GC–IMS detection process is shown in Fig.  1 and the 
three-dimensional data output with corresponding heat 
map is shown in Fig. 2.
Statistical analysis
The analysis of data created through FAIMS and GC–IMS 
analysis employs machine learning methods. In brief, they 
involve the construction of computerised algorithms that can 
learn from and make predictions on the output data from the 
instrument. The algorithms build a prediction model from a 
training set of known cases and use this knowledge to predict 
output decisions (diagnoses) on unknown cases. Five clas-
sification models were used; each dataset was compared with 
each model to find the most accurate for each specific set of 
samples. This form of analysis produces receiver operat-
ing characteristic (ROC) curves with area under the curve 
(AUC), sensitivity and specificity values calculated from the 
coordinates of the ROC plots. A schematic of the analysis 
pipeline is provided in Online Resource 2. All statistical 
analyses were carried out using the verification package in 
R studio (R Foundation for Statistical Computing, Vienna, 
Austria).
As CRC numbers were small within the screening pop-
ulation (incidence of 8–10%), a balancing technique was 
applied to the data to fairly match the non-CRC samples 
with the same number of CRC samples and avoid bias 
from an unbalanced control group. Balancing involved the 
well-described synthetic minority over-sampling technique 
(SMOTE), where artificially generated points are plotted to 
represent the control group as a whole and is used to provide 
a more fair representation [24].
Results
FAIMS analysis
A total of 163 samples were analysed. 93 (57%) were from 
males, median age of patients was 67 years, 12 (7.4%) were 
current smokers. 41 (25.4%) were ex-smokers and 109 
(67.2%) had never smoked. Patients were grouped into cat-
egories according to diagnosis for analysis. Diagnostic out-
comes for study participants are listed in Table 1.
Group (a) CRC vs normal control demonstrated the high-
est degree of separation with AUC 0.98 (95% CI 0.93–1.0) 
with 12 patients in each group. The corresponding ROC 
curve is shown in Fig. 3. Sensitivity and specificity were also 
high: 1.0 (95% CI 0.74–1) and 0.92 (95% 0.62–1), respec-
tively (Table 2).
Table 1  Diagnostic outcomes for study participants and distribution 
of CRC by site (total of 13 cancer sites as one patient had a synchro-
nous tumours)
*1 not fit enough for investigations, 7 declined investigations
^Inflammatory bowel disease: n = 7, rectal telangiectasia: n = 2, rec-
tal ulcer: n = 1, radiation proctitis: n = 1, inflammatory pseudopolyp: 
n = 1, non-specific sigmoid inflammation: n = 1, ischaemic sigmoid 
stricture: n = 1
Diagnosis Number (%)
Cancer Total 12 (7.6)
Rectum 4 (2.4)
Sigmoid 4 (2.4)
Descending colon 0
Transverse colon 1 (0.58)
Ascending colon 2 (1.17)
Cecum 2 (1.17)
Adenoma Total 80 (49.1)
High 17(10.5)
Intermediate 36 (21.1)
Low 27 (17.5)
Diverticular disease 14 (8.2)
Normal 37 (19.3)
Haemorrhoids 5 (2.9)
Other 14 (8.2)^
Excluded 8 (4.7)*
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In groups (b–e) CRC was grouped with adenomas and 
showed only modest AUC, sensitivity and specificity results, 
when attempting to classify groups according to diagnosis. 
The most accurate classification of the adenoma groups was 
seen in (b) CRC + all adenomas vs normal control; here sen-
sitivity was low at 0.48 (95% CI 0.38–0.59) but specificity 
was high at 0.89 (95% CI 0.75–0.97). In (f) when CRC was 
excluded, separation was low with sensitivity 0.56 (95% CI 
0.46–0.65).
A further set of analyses were carried out to investigate 
the classification of the adenoma groups in more depth and 
to compare CRC with three categories of adenoma: (g) high 
risk, (h) intermediate risk and (i) low risk, according to the 
BSG guidelines [25], the results are displayed in Table 1. 
High sensitivity was demonstrated when each adenoma 
group was compared with CRC. The most accurate overall 
classification was seen in CRC vs high-risk adenoma with 
a sensitivity of 0.83 (95% CI 0.52–0.98) and specificity of 
1 (95% CI 0.59–1).
GC–IMS analysis
One hundred and nine patient samples were analysed using 
the Silox GC–IMS instrument. Five comparator groups were 
devised according to outcome (Table 3).
As with the analysis using FAIMS, when comparing 
CRC vs normal control (group a) there was a high degree 
of separation with a sensitivity of 0.80 (95% CI 0.44–0.97) 
and specificity of 0.83 (95% CI 0.63–0.95). The correspond-
ing ROC curve is seen in Fig. 4. CRC vs other diagnoses 
also had a high sensitivity of 1.0 (95% CI 0.66–1), how-
ever, specificity dropped to 0.57 (95% CI 0.34–0.78). When 
CRC samples were grouped with adenomas and compared 
with other groups (those with any diagnosis other than CRC 
or adenoma) the sensitivity dropped to a modest level of 
0.71 (95% CI 0.58–0.81) with sensitivity 0.55 (0.39–0.70). 
Adenomas vs normal control showed a low level of separa-
tion, with a sensitivity of only 0.58 (95% CI 0.44–0.71) and 
specificity 0.62 (95% CI 0.41–0.81) (Table 3).
Table 2  Classification of BCSP study participants by outcome using FAIMS
Using sparse logistic regression and Gaussian process
Corresponding 95% CIs are stated in brackets. Numbers in brackets in group column denote sample number
BSCP bowel cancer screening programme, FAIMS field asymmetric waveform ion mobility spectrometry, CRC Colorectal cancer
Group AUC Sensitivity Specificity PPV NPV
a) CRC (12) vs normal (12) 0.98 (0.93–1) 1 (0.74–1) 0.92 (0.62–1) 0.92 1
b) CRC + all adenomas (93) vs normal (37) 0.64 (0.54–0.74) 0.48 (0.38–0.59) 0.89 (0.75–0.97) 0.92 0.41
c) CRC + high-risk adenomas (30) vs normal (37) 0.62 (0.48–0.76) 0.57 (0.37–0.75) 0.68 (0.5–0.82) 0.59 0.66
d) CRC + high-risk adenomas (30) vs other (70) 0.6 (0.47–0.73) 0.47 (0.28–0.66) 0.80 (0.68–0.89) 0.52 0.76
e) CRC + all adenomas (93)vs other (70) 0.56 (0.47–0.65) 0.91 (0.84–0.96) 0.25 (0.15–0.38) 0.64 0.67
f) Non-CRC (113) vs normal (37) 0.61 (0.51–0.71) 0.56 (0.46–0.65) 0.68 (0.5–0.82) 0.83 0.35
g) CRC (12) vs Adenoma (7) (hr) 0.92 (0.77–1) 0.83 (0.52–0.98) 1 (0.59–1) 1 0.78
h) CRC (12) vs Adenoma (12) (ir) 0.84 (0.67–1) 0.83 (0.52–0.98) 0.75 (0.43–0.95) 0.77 0.82
i) CRC (12) vs Adenoma (12) (lr) 0.83 (0.66–1) 0.75 (0.43–0.95) 0.92 (0.62–1) 0.90 0.79
Fig. 3  Receiver operating characteristic (ROC) curve for classifica-
tion of colorectal cancer (CRC) vs normal in bowel cancer screen-
ing programme (BCSP) patients (balanced) using the sparse logistic 
regression classifier using field asymmetric waveform ion mobility 
spectrometry(FAIMS)
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Discussion
This study explored the feasibility of a urinary VOC-
based test in the detection of CRC within the screening 
population that tested positive for faecal occult blood. The 
results, applying two different technologies—FAIMS and 
GC–IMS show consistency. Ability to distinguish CRC 
from normal control was high with AUC 0.98, sensitivity 
of 1.0 and specificity of 0.92. Ability to distinguish CRC 
from low-, intermediate- and high-risk adenomas was high 
with test accuracy ranging from 0.83 to 0.92 using FAIMS. 
Similarly, ability to distinguish CRC from normal control 
was high with AUC 0.82, sensitivity of 0.80 and specificity 
of 0.83 using GC–IMS.
CRC-specific VOCs are thought to occur via genetic and 
protein changes that cause peroxidation of the cell mem-
brane [26]. In addition, there is an increase in reactive oxy-
gen species within the cancer cell and alterations in the 
microbiome have a direct effect on the VOCs [27–30]. How 
distinct these changes are in the CRC group compared with 
other disease groups is yet to be fully elucidated.
The separation of CRC from normal controls was high, 
yet when CRC cases were grouped with adenomas the accu-
racy dropped significantly. This suggests that CRC has a 
unique VOC profile or signature that distinguishes it from 
other gastrointestinal pathologies. When this profile is com-
bined with other (non-neoplastic) gastrointestinal disorders, 
the VOC signature is not sufficiently distinct to allow correct 
classification.
In the case of CRC vs different adenoma risk groups, the 
separation was again high. This implies that it is possible 
to separate malignant from pre-malignant disease based on 
urinary VOC signature patterns. When considering this as 
a basis for a screening test, the high specificity suggests the 
potential of using VOC-based analysis to reduce the number 
of unnecessary endoscopic procedures. This set of results 
warrant further exploration, to ascertain whether the separa-
tion seen is simply because the adenoma group represents 
another non-CRC group or whether there are changes spe-
cific to the VOC signature of colonic adenomas that make it 
more distinct from CRC than other groups.
To the best of our knowledge this is the first study to 
specifically examine adenoma detection by urinary VOCs. 
Applying FAIMS, the adenoma group showed poor separa-
tion from normal controls. Previous studies have reported on 
colonic adenoma detection by faecal [31] VOCs with low to 
modest test accuracy (sensitivity of 0.62). Advanced ade-
noma detection using breath VOCs [32, 33] demonstrated 
more encouraging results (sensitivity 1.0). These conflicting 
results suggest that there is more work needed to establish 
the mechanism of VOC signature changes in the presence 
Fig. 4  Receiver operating characteristic (ROC) curve for classifica-
tion of colorectal cancer (CRC) vs normal using GC–IMS. [Gaussian 
process (GP) classifier]
Table 3  Classification of BCSP study participants using GC–IMS using Gaussian process or support vector machine
Corresponding 95% CI are in brackets. Study numbers are stated in the group column in brackets
BSCP bowel cancer screening programme, GC–IMS gas chromatography coupled with ion mobility spectrometry, AUC area under the curve, 
CRC colorectal cancer, PPV positive predictive value, NPV negative predictive value
Group AUC Sensitivity Specificity PPV NPV
CRC (10) vs normal (24) 0.82 (0.67–0.97) 0.80 (0.44–0.97) 0.83 (0.63–0.95) 0.67 0.91
CRC + high-risk adenomas (23) vs normal(24) 0.53 (0.36–0.70) 0.48 (0.27–0.69) 0.67 (0.45–0.84) 0.58 0.57
CRC (10) vs other (20) 0.77 (0.60–0.94) 1 (0.66-1) 0.57 (0.34–0.78) 0.5 1
CRC + all adenomas (65) vs other (42) 0.61 (0.49–0.72) 0.71 (0.58–0.81) 0.55 (0.39–0.70) 0.71 0.55
All adenomas (55) vs normal (24) 0.61 (0.47–0.75) 0.58 (0.44–0.71) 0.62 (0.41–0.81) 0.78 0.39
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of colonic adenomas and other gastrointestinal disorders. 
This is vital as adenomas represent a pre-malignant process 
with adenoma detection intrinsically linked to CRC mor-
tality [34–36]. Adenoma detection is particularly pertinent 
to the BCSP population given the high adenoma incidence 
of approximately 50%, compared with around 15% in the 
average population [25, 37]. As faecal testing relies on the 
presence or absence of blood, it is poor at detecting adeno-
mas, as most do not bleed [38]. If the patients with CRC and 
adenomas could be better identified using a urine test, this 
could revolutionise the screening process. Urine sampling 
has been demonstrated to be more acceptable to patients 
than faecal in the previous work by our group. In this study, 
recruitment was > 90%, far exceeding the FOBT uptake of 
approximately 60%.
The analytical technology associated with VOC detec-
tion is constantly being improved, with particular focus on 
refinement of data software and ion capture technique. The 
benefits of using FAIMS as the detection method of choice, 
have been described in the literature before [21], but the 
level of repeatability required for equipping the clinical set-
ting with this technology has not yet been demonstrated.
This is the first reported study demonstrating the appli-
cation of GC–IMS in CRC detection [39, 40]. GC–IMS 
have several advantages as a clinical tool. It is simple to 
use, meaning specialist training is not required. Also, it is 
portable, thus in theory, could be transported to the clinical 
area of need for instant analysis. Finally, due to the IMS 
component, it has the technology to isolate and identify the 
chemical compounds within the urine sample. This has the 
potential to broaden current understanding of CRC patho-
genesis and also narrow the target window of chemicals that 
comprise the VOC profile in CRC. However, at this point 
the chemical National Institute of Standards and Technol-
ogy (NIST) library required to perform this step is currently 
small.
It is important to highlight that the bowel screening 
patient group recruited for this study consisted of patients 
that had a positive FOBT. The authors recognise the impor-
tance of examining FOBT negative patients too when 
comparing a new screening tool with FOBT, but were con-
strained by the BCSP recommendations.
The current guaiac FOBT has poor selectivity for CRC, 
therefore, it would be interesting to repeat this experiment 
once the FIT is introduced for UK bowel screening. It has 
both superior sensitivity and specificity compared to the cur-
rent FOBT. Combining VOC detection with FIT as a two-
stage test in the asymptomatic population that forms the 
basis of a decision-making algorithm for further investiga-
tions, is an area of interest that may hold the most potential 
in the field of VOC diagnostics in CRC [41], rather than the 
use of VOC detection as a stand alone test. Further research 
could also test this algorithm (FIT plus urinary VOC profile) 
in the symptomatic population, where risk stratification is 
extremely difficult based on symptoms alone.
A limitation of this study was the small sample size for 
the CRC group, but this reflects the nature of the screen-
ing population with low CRC detection rates of around 8%. 
Machine learning algorithms that were used to analyse both 
sets of date always risk the possibility of overfitting of the 
data. This was minimised using a cross-validation technique 
and using two different technologies.
Conclusions
Our results indicate detection of CRC and adenomas through 
urinary VOCs within a screening population is feasible. 
CRC can be correctly classified from control and adeno-
mas using FAIMS and GC–IMS, but the classification of 
adenomas from control was poor. This approach to disease 
detection faces multiple challenges, that reflect the complex-
ity of human disease and it is likely biomarker-led disease 
detection will require a panel of markers rather than focus on 
one specific marker in the screening population.
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